Identification of as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.

Date publication

décembre 2022

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOREL Christian

Tous les auteurs :
Spira A, Awada A, Isambert N, Lorente D, Penel N, Zhang Y, Ojalvo LS, Hicking C, Rolfe PA, Ihling C, Dussault I, Locke G, Borel C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36568239

Résumé

We report the clinical activity, safety, and identification of a predictive biomarker for bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFβRII (a TGF-β "trap") fused to a human IgG1 mAb blocking PD-L1, in patients with advanced triple-negative breast cancer (TNBC).

Mots clés

PD-L1, TGF-β, bintrafusp alfa, triple-negative breast cancer, tumor microenvironment

Référence

Front Oncol. 2022 12 8;12:981940